Introduction {#sec1}
============

Breast cancer is one of the most common cancers worldwide, accounting for 25.1% of all cancers \[[@bib1]\]. The data from "Surveillance, Epidemiology, and End Results" of the United States show that there were approximately 246,660 newly diagnosed cases of breast cancer in 2016, and the total number of breast cancer patients reached 3,560,570 \[[@bib2]\]. Cancer was the top leading cause of death in the past decade, accounting for 28% of all deaths in Taiwan, where breast cancer is fourth leading cause of cancer-related mortality and the most common cancer among women. The cancer mortality of women in Taiwan reached 157.9 per 100,000 people, and 2,000 women died of breast cancer in 2017. There are many treatment modalities including surgery, radiotherapy, chemotherapy, target therapy, and hormone therapy for breast cancer patients \[[@bib2]\].

The diagnosis and treatment of cancer is complex. In 1995, a Multidisciplinary Team (MDT) care policy was implemented to improve the care quality of cancer patients in the United Kingdom \[[@bib3]\]. MDTs consist of many professionals such as medical, nursing, and allied professionals and diagnostic experts to determine the optimal treatment pathway for individual patients \[[@bib4],[@bib5]\]. Previous studies show that MDT care is helpful in making clinical decision \[[@bib6], [@bib7], [@bib8]\]. MDT care can intercept 98.8% of all medication errors and improve the quality of care \[[@bib9],[@bib10]\]. After multidisciplinary care was introduced in the United Kingdom, breast cancer mortality in the intervention area was 18% lower than that in the non-intervention area \[[@bib11]\]. In another study, the MDT had the following characteristics: comprising specialist breast cancer surgeons, pathologists, oncologists, radiologists, and specialist nurses; working with evidence-based guidelines, written by the specialist breast surgeon whose patients had the highest survival rates; weekly formal meetings to discuss results for individual patients; and audited clinical activity and results recorded at regular intervals \[[@bib11]\]. The introduction of MDT care is associated with lower medical cost, improved medical care quality, and higher survival rate \[[@bib4],[@bib12],[@bib13]\]. In Australia, multidisciplinary care is widely recommended for managing breast cancer \[[@bib14],[@bib15]\]. MDT care has the potential to reduce mortality, improve quality of life, and reduce healthcare costs for early breast cancer patients \[[@bib14],[@bib15]\]. MDT care was introduced in Taiwan since 2003 for improving the quality of care and survival rates of breast cancer patients. The MDTs include specialist breast cancer surgeons, pathologists, oncologists, and radiologists. They hold regular MDT formal meetings to design individual treatment programs for breast cancer patients.

Obesity is a risk factor for both breast cancer and recurrence \[[@bib16]\]. A previous study conducted in Germany showed the recurrence and mortality rates of breast cancer patients who did not exercise were higher than the rates of those who did (HR, 1.71) \[[@bib17]\]. Another study in Germany showed the recurrence rates for breast cancer patients in stages I and II were 15% and 16.8%, respectively \[[@bib18]\]. A previous study also showed the recurrence rate was 10.4% within five years of diagnosis \[[@bib19]\]. This study used national large-scale data to investigate whether MDT care in breast cancer affects the recurrence rate; concurrently, we also aimed to examine the impact of other relevant factors on recurrence. This will provide a reference base for future treatment of breast cancer patients, mainly by increasing the survival rate and decreasing the recurrence rate.

Material and methods {#sec2}
====================

Study participants {#sec2.1}
------------------

This was a retrospective matched cohort study. We included 50,982 newly diagnosed breast cancer patients from 2004 to 2010. The newly diagnosed breast cancer patients were defined as ICD-O-3 with C50.0--C50.6 and C50.8--C50.9 without any prior diagnosis of cancer. Male breast cancer patients were excluded (328). Other exclusion criteria were as follows: breast cancer in situ (3,975), stage 0 and stage IV (9,480), no surgical treatment in one year from diagnosis (5,419), death within three months of diagnosis (64), treatment in clinics (186), and patients with some missing data (2,750). Finally, 28,780 patients were included. We used propensity score matching to match the group of breast cancer patients who received MDT care to those who did not at a ratio of 1:1.

Data sources {#sec2.2}
------------

The data for this study were obtained from the Taiwan Cancer Registry, which was also used to recruit the study participants. We also linked the data to the National Health Insurance Research Database (NHIRD) and the Cause of Death File from 2004 to 2014 that was provided by the Ministry of Health and Welfare in Taiwan. The accuracy of the Taiwan Cancer Registry (TCR) and NHIRD is excellent. The TCR, a population-based cancer registry, was founded in 1979. The registry is organized and funded by the Ministry of Health and Welfare. The TCR Database (TCRD) records data of all types of cancers diagnosed and treated in Taiwan. The completeness (97%) and data quality of the TCRD is excellent \[[@bib20]\]. [Fig. 1](#fig1){ref-type="fig"} shows the flowchart of study participants.Fig. 1Flow chart of study participants.Fig. 1

Definition and description of variables {#sec2.3}
---------------------------------------

The general characteristics of breast cancer patients were examined. Age was defined as the age at which the patient had a confirmatory diagnosis based on pathological findings. The financial status of the patient was based on monthly salary. The degree of urbanization at the patient's place of residence was used to represent environmental factors. The level of urbanization was based on seven levels of classification from highly urbanized developed cities (level 1) to remote areas (level 7). The health status of the patients included data on whether the patient had other catastrophic illnesses besides cancer, their Charlson Comorbidity Index (CCI), and the stage of breast cancer. The definition of catastrophic illness was based on the 30 types of catastrophic illnesses or injuries as defined by the National Health Insurance Administration, including stroke, chronic kidney failure, systemic lupus erythematosus, type I diabetes, and severe mental illness. The degree of comorbidity was classified into three levels based on the CCI. Tumor staging was based on the guidelines of the American Joint Committee on Cancer (sixth edition for tumors diagnosed from 2004 to 2009; seventh edition for tumors diagnosed in 2010), which includes stages I, II, and III. Hospital attributes includes hospital ownership (public or private institutions). The physician's service volume was divided into low, medium, and high on the basis of quartiles: service volumes of \<25%, 25--75%, and \>75% were low, medium, and high, respectively. Patients were considered to be enrolled in MDT care if they received MDT treatment after pathological diagnosis of breast cancer and declared the MDT treatment fees in the NHI database (47079B). The definitions of relevant treatments were based on the relevant treatment codes was declared in the NHI database, which were checked against the treatment registration information in the Taiwan Cancer Information Database. Recurrence was defined as the first recurrence after disease-free or remission period as recorded in the TCR. We observed all participants for two years since the first diagnosis of breast cancer to check for recurrence. The death rate was based on the data from the Cause of Death File until 2014.

Main outcome measurements {#sec2.4}
-------------------------

The main outcomes examined in this study were the recurrence and survival rates of breast cancer patients. The death and recurrence rates were based on patient data from the NHI database and these were compared with the Taiwan Cause of Death archives for confirmation.

Statistical analysis {#sec2.5}
--------------------

The current research is a retrospective and longitudinal controlled cohort study. We employed descriptive statistics to analyze the general characteristics, financial status, environmental factors, health status of patients, hospital attributes, and status of enrolment in MDT of breast cancer patients who had a confirmatory diagnosis as per pathological findings from 2004 to 2010. We used Propensity score to match the group of breast cancer patients who received MDT care to those who did not at a ratio of 1:1. Chi-square test was used to analyze the patients' age, monthly salary, degree of urbanization of the patient's place of residence, catastrophic illnesses besides cancer, and CCI after matching. Then, bivariate analysis was performed using the log-rank test to determine whether there were significant differences between recurrence status by the end of 2012 and general characteristics, financial status, environmental factors, health status of patients, hospital attributes, and enrolment in MDT. We then used univariate Cox proportional hazards regression to analyze relevant prognostic factors that affect the recurrence rates of breast cancer patients. The adjusted Cox proportional hazards model was used to investigate the relative risk of survival of breast cancer patients with or without MDT enrolment, after controlling for related variables. Independent variables included patient characteristics, financial status, environmental factors, health status, hospital attributes, and enrolment in MDT. The dependent variable was recurrence. Lastly, after controlling for relevant variables, the adjusted Cox proportional hazards model was used to generate the survival curves for breast cancer patients in various stages with or without MDT care.

All statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Inc., Cary, NC, USA). A p value of \<0.05 was regarded statistically significant, and all tests were two-sided. This study has been approved by the research ethics committee of China Medical University Hospital in Taiwan (IRB Number: CRREC-106-008).

Results {#sec3}
=======

Demographic characteristics of the study population {#sec3.1}
---------------------------------------------------

After matching by propensity score, a total of 18,532 breast cancer patients were included in the study ([Table 1](#tbl1){ref-type="table"}). There was no significant difference (p \> 0.05) in age, monthly salary, CCI score, environmental factors, health status of patients, hospital attributes and other characteristics between MDT care participants and non-MDT care participants.Table 1Bivariate analysis of breast cancer patients' characteristics with or without MDT care after matching.Table 1\
Variablesafter matchingP-value^a^Totalwith MDT carewithout MDT careN%N%N%**Total number**18,532100.009,26650.009,26650.00**Age**0.792\<358764.734564.924204.5335-444,25322.952,12022.882,13323.0245-547,09538.293,53638.163,55938.4155-644,01021.642,01121.701,99921.57≧652,29812.401,14312.341,15512.46**CCI score**0.148 013,29771.756,61071.346,68772.17 13,48218.791,74118.791,74118.79 ≧21,7539.469159.878389.04**Monthly salary (NTD)**0.224≦17,2804,42323.872,16523.362,25824.3717,281--22,0805,56530.032,79630.172,76929.8822,081--36,3003,96621.402,02921.901,93720.90≧36,3014,57824.702,27624.562,30224.84**Urbanization level**0.352Level 17,24539.093,57238.553,67339.64Level 2 + Level 38,24544.494,14244.704,10344.28Level 4 + Level 52,24012.091,13512.251,10511.93Level 6 + Level 78024.334174.503854.15**Cancer stage**0.188Stage I6,17233.303,09233.373,08033.24Stage II8,29944.784,09844.234,20145.34Stage III4,06121.912,07622.401,98521.42**Hospital ownership**0.114Public5,45429.432,67828.902,77629.96Private13,07870.576,58871.106,49070.04**Physician services volume**0.309Low3,81920.611,90220.531,91720.69Medium9,84653.134,88552.724,96153.54High4,86726.262,47926.752,38825.77Variablesafter matchingP-value[a](#tbl1fna){ref-type="table-fn"}Totalwith MDT carewithout MDT careN%N%N%**Treatment**0.211 Surgery6923.733383.653543.83 Surgery + Radiotherapy5412.922873.102542.74 Surgery + Chemotherapy1,2006.485956.426056.53 Surgery + Hormone therapy2,26512.221,10911.971,15612.48 Surgery + Radiotherapy + Chemotherapy2,33912.621,19112.851,14812.39 Surgery + Radiotherapy + Hormone therapy2,57013.871,29513.981,29513.76 Surgery + Chemotherapy + Hormone therapy2,38712.881,18412.781,20312.98 Surgery + Chemotherapy + Drug890.48520.56370.40 Surgery + Chemotherapy + Hormone therapy + Drug1040.56590.64450.49 Surgery + Radiotherapy + Chemotherapy + Drug3271.761791.931481.60 Surgery + Radiotherapy + Chemotherapy + Hormone therapy5,66530.572,79030.112,87531.03 Surgery + Radiotherapy + Chemotherapy + Hormone therapy + Drug3531.901872.021661.79[^2]

The effect of MDT care and relevant variables on recurrence risk of breast cancer patients {#sec3.2}
------------------------------------------------------------------------------------------

We used log-rank test to analyze the variables of breast cancer patients with or without recurrence. [Table 2](#tbl2){ref-type="table"} shows that the recurrence rate of the MDT group was significantly lower than that of the non-MDT group (HR, 0.84; 95%CI: 0.70--0.99; p \< 0.05). The Cox proportional hazards model was utilized to analyze the relative risk in recurrence between MDT group and non-MDT groups after adjusting for demographic characteristics, CCI score, monthly salary, urbanization level of residence area, cancer stage, hospital ownership, treatment modality, and physician service volume. [Fig. 2](#fig2){ref-type="fig"} shows the KM curve of recurrence rate of breast patients with or without MDT care. [Fig. 3](#fig3){ref-type="fig"} shows the KM curve of recurrence rate in different stages of breast cancer.Table 2Bivariate analysis of variables in breast cancer patients with or without recurrence and relative risk of recurrence.Table 2VariablesTotalNo recurrenceRecurrenceP-value^a^AdjustedN%N%N%HR95% CIP-value^b^**Total number**18,53210018,02197.245112.76**MDT care**0.101Yes9,266509,02997.442372.56No9,266508,99297.042742.960.840.70.990.047**Age**0.002\<358764.7385397.37232.6335--444,25322.954,15897.77952.230.890.571.410.62845--547,09538.296,91397.431822.570.940.611.460.79355--644,01021.643,88796.931233.070.960.611.510.854≧652,29812.42,21096.17883.8310.621.620.998**Mean age (SD)**51.1711.0151.1110.9753.0311.95\<0.001**CCI score**0.384013,29771.7512,93997.313582.6913,48218.793,38697.24962.761.050.831.330.669≧21,7539.461,69696.75573.251.150.861.550.351**Monthly salary (NTD)**\<0.001≦17,2804,42323.874,27996.741443.2617,281--22,0805,56530.035,38796.81783.21.040.831.30.73322,081--36,3003,96621.43,87497.68922.320.780.61.020.065≧36,3014,57824.74,48197.88972.120.770.590.990.048**Urbanization level**0.37Level 17,24539.097,06297.471832.53Level 2 + Level 38,24544.498,00797.112382.890.980.811.20.854Level 4 + Level 52,24012.092,17797.19632.810.860.641.160.332Level 6 + Level 78024.3377596.63273.370.950.621.430.791VariablesTotalNo recurrenceRecurrenceP-value^a^AdjustedN%N%N%HR95% CIP-value^b^**Cancer stage**\<0.001Stage I6,17233.36,12499.22480.78Stage II8,29944.788,12697.921732.082.561.843.56\<0.001Stage III4,06121.913,77192.862907.148.696.2712.06\<0.001**Hospital ownership**0.005Public5,45429.435,33297.761222.24Private13,07870.5712,68997.033892.971.160.941.420.177**Physician services volume**\<0.001Low3,81920.613,61694.682035.32Medium9,84653.139,66398.141831.860.330.270.4\<0.001High4,86726.264,74297.431252.570.390.310.49\<0.001**Treatment**\<0.001 Surgery6923.7367297.11202.89 Surgery + Radiotherapy5412.9250893.9336.12.241.283.930.005 Surgery + Chemotherapy1,2006.481,15596.25453.751.440.852.450.176 Surgery + Hormone therapy2,26512.222,23898.81271.190.550.310.990.045 Surgery + Radiotherapy + Chemotherapy2,33912.622,22795.211124.791.220.751.990.426 Surgery + Radiotherapy + Hormone therapy2,57013.872,54198.87291.130.570.321.020.059 Surgery + Chemotherapy + Hormone therapy2,38712.882,34698.28411.720.830.481.420.49 Surgery + Chemotherapy + Drug890.487280.91719.16.293.2412.22\<0.001VariablesTotalNo recurrenceRecurrenceP-value[a](#tbl2fna){ref-type="table-fn"}AdjustedN%N%N%HR95% CIP-value[b](#tbl2fnb){ref-type="table-fn"} Surgery + Chemotherapy + Hormone therapy + Drug1040.569793.2776.732.491.045.960.041 Surgery + Radiotherapy + Chemotherapy + Drug3271.7628286.244513.763.031.745.25\<0.001 Surgery + Radiotherapy + Chemotherapy + Hormone therapy5,66530.575,54797.921182.080.630.391.040.07 Surgery + Radiotherapy + Chemotherapy + Hormone therapy + Drug3531.933695.18174.821.260.652.480.495[^3][^4]Fig. 2Kaplan-Meier curve of recurrence rate of breast cancer patients with or without multidisciplinary team care. The solid line showed the recurrence rate of breast cancer patients who received MDT care. The dotted line showed the recurrence rate of breast cancer patients who did not receive MDT care.Fig. 2Fig. 3Kaplan-Meier curve of recurrence rate in different stages of breast cancer with or without multidisciplinary team care. The solid line showed the recurrence rate of breast cancer patients who received MDT care in stages I, II, and III. The dotted line showed the recurrence rate of breast cancer patients who did not receive MDT care in stages I, II, and III.Fig. 3

The effect of MDT care and relevant variables on mortality risk of breast cancer patients {#sec3.3}
-----------------------------------------------------------------------------------------

We carried out log rank test to analyze the survival rate of breast cancer patients with or without MDT care and with or without recurrence ([Table 3](#tbl3){ref-type="table"}). The mortality rate of the MDT care group (12.48%) was lower than that of the non-MDT care group (13.05%). The mortality rate of the breast cancer patients with recurrence (74.95%) was significantly higher than that of patients without recurrence (16.19%) (p \< 0.05). The Cox proportional hazards model was utilized to analyze the relative risk of death between the MDT care and non-MDT group and also between the recurrence and non-recurrence group after adjusting for demographic characteristics, CCI score, monthly salary, urbanization level, cancer stage, hospital ownership, treatment modality, and physician's service volume. The relative risk of mortality was significantly lower for the MDT care than for the non-MDT group (HR: 0.89, 95%CI: 0.82--0.96). The relative risk of mortality was significantly higher for the recurrence group than for the non-recurrence group (HR, 8.48; 95%CI: 7.53--9.54).Table 3Bivariate analysis of variables in breast cancer patients with survival or death and relative risk of survival.Table 3VariablesTotalSurvivalDeathP-value^a^Adjusted modelN%N%N%HR95% CIP-value^b^**Total number**18,53210016,16787.242,36512.76**MDT care**0.087 No (ref.)9,266508,05786.951,20913.05 Yes9,266508,11087.521,15612.480.890.820.960.004**Recurrence**\<0.001 No (ref.)18,02197.2416,03983.811,98216.19 Yes5112.7612825.0538374.958.487.539.54\<0.001**Age**\<0.001 \<35(ref.)8764.7377188.0110511.99 35--444,25322.953,85890.713959.290.750.610.930.01 45--547,09538.296,35889.6173710.390.820.6610.053 55--644,01021.643,46786.4654313.540.990.81.220.923 ≧652,29812.41,71374.5458525.461.651.332.06\<0.001**Mean age (MSD)**51.1711.0150.5610.4855.3413.35\<0.001**CCI score**\<0.001 0 (ref.)13,29771.7511,74988.361,54811.64 13,48218.793,02586.8845713.121.020.911.130.762 ≧21,7539.461,39379.4636020.541.361.211.54\<0.001**Monthly salary**\<0.001 ≦17,280 (ref.)4,42323.873,78485.5563914.45 17,281--22,0805,56530.034,74385.2382214.771.050.941.170.386 22,081--36,3003,96621.43,51088.545611.51.010.91.150.832 ≧36,3014,57824.74,13090.214489.790.890.790.960.041VariablesTotalSurvivalDeathP-value^a^Adjusted modelN%N%N%HR95% CIP-value^b^**Urbanization level**\<0.001 Level 1 (ref.)7,24539.096,41488.5383111.47 Level 2 +Level 38,24544.497,17887.061,06712.940.980.891.080.685 Level 4 +Level 52,24012.091,90184.8733915.130.970.851.110.648 Level 6 +Level 78024.3367484.0412815.960.910.751.110.359**Cancer stage**\<0.001 Stage I (ref.)6,17233.35,93196.12413.9 Stage II8,29944.787,37888.992111.12.892.53.34\<0.001 Stage III4,06121.912,85870.381,20329.629.047.7810.51\<0.001**Hospital ownership**\<0.001 Public (ref.)5,45429.434,84788.8760711.13 Private13,07870.5711,32086.561,75813.441.161.051.280.003**Physician services volume**\<0.001 Low (ref.)3,81920.612,98778.2183221.79 Medium9,84653.138,83789.751,00910.250.40.360.44\<0.001 High4,86726.264,34389.2352410.770.320.280.36\<0.001VariablesTotalSurvivalDeathP-value[a](#tbl3fna){ref-type="table-fn"}Adjusted modelN%N%N%HR95% CIP-value[b](#tbl3fnb){ref-type="table-fn"}Treatment\<0.001 Surgery (ref.)6923.7358284.111015.9 Surgery + Radiotherapy5412.9245483.928716.081.150.871.530.332 Surgery + Chemotherapy1,2006.481,00483.6719616.331.361.081.730.01 Surgery + Hormone therapy2,26512.221,98587.6428012.360.970.781.220.815 Surgery + Radiotherapy + Chemotherapy2,33912.621,88780.6845219.321.080.871.340.479 Surgery + Radiotherapy + Hormone therapy2,57013.872,34591.252258.750.920.731.170.497 Surgery + Chemotherapy + Hormone therapy2,38712.882,17190.952169.050.860.681.090.216 Surgery + Chemotherapy + Drug890.486471.912528.091.110.711.720.657 Surgery + Chemotherapy + Hormone therapy + Drug1040.569389.421110.580.80.431.490.478 Surgery + Radiotherapy + Chemotherapy + Drug3271.7624574.928225.081.10.821.490.516 Surgery + Radiotherapy + Chemotherapy + Hormone therapy5,66530.575,03288.8363311.170.750.610.930.01 Surgery + Radiotherapy + Chemotherapy + Hormone therapy + Drug3531.930586.44813.60.950.671.350.761[^5][^6]

Discussion {#sec4}
==========

After matching by propensity score, we found that the recurrence rate of the MDT care group was significantly lower than that of the non-MDT care group (HR, 0.84; 95%CI: 0.70--0.99, p \< 0.05). The relative risk of mortality was significantly lower for the MDT care group than for the non-MDT care group (HR, 0.89; 95%CI: 0.82--0.96). The relative risk of mortality for the recurrence group was significantly higher than that for non-recurrence group (HR, 8.48; 95%CI: 7.53--9.54).

MDT care can significantly decrease the mortality risk of breast cancer patients \[[@bib9], [@bib10], [@bib11]\]. Although intrinsically multidisciplinary care should be associated with better survival, there remains a paucity of supporting evidence \[[@bib21]\]. However, a few studies discussed the underlying mechanisms of MDT care, namely team focus, enhanced structure and process, and improved team performance, resulting in better outcomes in terms of survival rates and patient satisfaction \[[@bib22]\]. The most important parts of MDT care are the team members, evidence-based guidelines, regular formal meetings, and personalized treatment programs \[[@bib11]\]. In Taiwan, the MDT program faced problems, such as excessive caseload, low attendance at MDT meetings, poor teamwork, lack of leadership, role ambiguity, and no attention to holistic needs \[[@bib23]\]. Previous studies show that the MDTs in most countries consist of medical oncologists (95%), surgical oncologists (95%), radiation oncologists (90%), pathologists (84%), radiologists (73%), and specialist nurses (49%). The frequency of MDT meetings in most countries (82%) is once per week \[[@bib24]\]. In our study, data on low attendance at MDT meetings, poor teamwork, lack of leadership, and role ambiguity were not available.

Another study showed that specialist nurses were important for evaluating the holistic needs of breast cancer patients and improving their life quality \[[@bib23]\]. A previous systemic review showed that MDT care led to precise diagnosis of cancer stage before surgery \[[@bib25]\]. There was not enough evidence of MDT care improving the survival rate of breast cancer patients \[[@bib25]\]. There were some differences in the effect of MDT care on breast cancer patients between these studies. The main cause could be the different settings of MDT including teamwork, performance, and leadership. Previous studies highlighted the need for quality indicators for measuring the effect of MDT \[[@bib26]\]. It is important to reevaluate the structure and models of MDT care to ensure that they are efficient \[[@bib23],[@bib27]\]. However, there is no nationwide study on the effect of MDT policy on the recurrence of breast cancer. Therefore, we recommend that in future policies, MDT should be included to reduce the recurrence rates of breast cancer.

We found that the recurrence risk of breast cancer patients with a monthly salary of ≥36,301 was significantly lower than that of patients with a monthly salary of ≤17,280 (HR, 0.77; 95%CI: 0.59--0.99). Further, the mortality risk of breast cancer patients increased as the monthly salary decreased (HR, 0.89; 95%CI: 0.79--0.96; p \< 0.05). Previous studies showed that breast cancer patients with low education and neighborhood-level socioeconomic status had 1.4 to 2.7 times worse all-cause survival than patients with high education, neighborhood-level and socioeconomic status \[[@bib28]\]. Another study stated that the mortality risk for low socioeconomic level was significantly higher than that for high socioeconomic level (HR, 1.08; 95%CI: 1.05--1.11) \[[@bib29]\]. Our results were consistent with these findings.

Previous studies showed that the five-year survival rate decreased with advanced stages of breast cancer (from 97.5% to 18.4%) \[[@bib30]\]. Similarly, another previous study showed that the five-year survival rate was 98%--23.4% from stage I to stage IV \[[@bib31]\]. We observed the same trend. The five-year survival rate was 61.61%--5.11% from stage I to stage IV of breast cancer.

Conclusions {#sec5}
===========

We collected nationwide data of 18,532 breast cancer patients, which, to the best of our knowledge, is the first nationwide study discussing policy-related issue. After matching by propensity score, the recurrence risk of the MDT care group was significantly lower than that of the non-MDT care group (HR, 0.84; p \< 0.05). The mortality risk of breast cancer patients receiving MDT care was significantly lower than that of patients not receiving MDT care (HR, 0.89; p \< 0.05). MDT policy should be offered in breast cancer care in the future.

Limitations {#sec6}
===========

Secondary data from the National Health Insurance Research Database was employed for this study. The information on individual lifestyle and health behaviors, which may also affect the result, was not available. Disease-free survival was also not evaluated in this study.
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